149 related articles for article (PubMed ID: 20628426)
1. Dual endothelin receptor antagonism prevents remodeling of resistance arteries in diabetes.
Sachidanandam K; Portik-Dobos V; Kelly-Cobbs AI; Ergul A
Can J Physiol Pharmacol; 2010 Jun; 88(6):616-21. PubMed ID: 20628426
[TBL] [Abstract][Full Text] [Related]
2. Glycemic control prevents microvascular remodeling and increased tone in type 2 diabetes: link to endothelin-1.
Sachidanandam K; Hutchinson JR; Elgebaly MM; Mezzetti EM; Dorrance AM; Motamed K; Ergul A
Am J Physiol Regul Integr Comp Physiol; 2009 Apr; 296(4):R952-9. PubMed ID: 19176890
[TBL] [Abstract][Full Text] [Related]
3. Evidence for vasculoprotective effects of ETB receptors in resistance artery remodeling in diabetes.
Sachidanandam K; Portik-Dobos V; Harris AK; Hutchinson JR; Muller E; Johnson MH; Ergul A
Diabetes; 2007 Nov; 56(11):2753-8. PubMed ID: 17670915
[TBL] [Abstract][Full Text] [Related]
4. Endothelial endothelin B receptor-mediated prevention of cerebrovascular remodeling is attenuated in diabetes because of up-regulation of smooth muscle endothelin receptors.
Kelly-Cobbs AI; Harris AK; Elgebaly MM; Li W; Sachidanandam K; Portik-Dobos V; Johnson M; Ergul A
J Pharmacol Exp Ther; 2011 Apr; 337(1):9-15. PubMed ID: 21205912
[TBL] [Abstract][Full Text] [Related]
5. Dual endothelin receptor antagonism with bosentan reverses established vascular remodeling and dysfunctional angiogenesis in diabetic rats: relevance to glycemic control.
Abdelsaid M; Kaczmarek J; Coucha M; Ergul A
Life Sci; 2014 Nov; 118(2):268-73. PubMed ID: 24447630
[TBL] [Abstract][Full Text] [Related]
6. Alterations in vascular matrix metalloproteinase due to ageing and chronic hypertension: effects of endothelin receptor blockade.
Spiers JP; Kelso EJ; Siah WF; Edge G; Song G; McDermott BJ; Hennessy M
J Hypertens; 2005 Sep; 23(9):1717-24. PubMed ID: 16093917
[TBL] [Abstract][Full Text] [Related]
7. Type-2 diabetes-induced changes in vascular extracellular matrix gene expression: relation to vessel size.
Song W; Ergul A
Cardiovasc Diabetol; 2006 Feb; 5():3. PubMed ID: 16503991
[TBL] [Abstract][Full Text] [Related]
8. Effect of chronic and selective endothelin receptor antagonism on microvascular function in type 2 diabetes.
Sachidanandam K; Elgebaly MM; Harris AK; Hutchinson JR; Mezzetti EM; Portik-Dobos V; Ergul A
Am J Physiol Heart Circ Physiol; 2008 Jun; 294(6):H2743-9. PubMed ID: 18424628
[TBL] [Abstract][Full Text] [Related]
9. Type 2 diabetes causes remodeling of cerebrovasculature via differential regulation of matrix metalloproteinases and collagen synthesis: role of endothelin-1.
Harris AK; Hutchinson JR; Sachidanandam K; Johnson MH; Dorrance AM; Stepp DW; Fagan SC; Ergul A
Diabetes; 2005 Sep; 54(9):2638-44. PubMed ID: 16123352
[TBL] [Abstract][Full Text] [Related]
10. Endothelin-1-mediated cerebrovascular remodeling is not associated with increased ischemic brain injury in diabetes.
Li W; Kelly-Cobbs AI; Mezzetti EM; Fagan SC; Ergul A
Can J Physiol Pharmacol; 2010 Aug; 88(8):788-95. PubMed ID: 20725136
[TBL] [Abstract][Full Text] [Related]
11. Distortion of K
Angus JA; Hughes RJA; Wright CE
Pharmacol Res Perspect; 2017 Dec; 5(6):. PubMed ID: 29226623
[TBL] [Abstract][Full Text] [Related]
12. Late dual endothelin receptor blockade with bosentan restores impaired cerebrovascular function in diabetes.
Abdelsaid M; Ma H; Coucha M; Ergul A
Life Sci; 2014 Nov; 118(2):263-7. PubMed ID: 24434796
[TBL] [Abstract][Full Text] [Related]
13. Endothelin antagonism prevents early EGFR transactivation but not increased matrix metalloproteinase activity in diabetes.
Portik-Dobos V; Harris AK; Song W; Hutchinson J; Johnson MH; Imig JD; Pollock DM; Ergul A
Am J Physiol Regul Integr Comp Physiol; 2006 Feb; 290(2):R435-41. PubMed ID: 16239374
[TBL] [Abstract][Full Text] [Related]
14. Effect of chronic endothelin receptor antagonism on cerebrovascular function in type 2 diabetes.
Harris AK; Elgebaly MM; Li W; Sachidanandam K; Ergul A
Am J Physiol Regul Integr Comp Physiol; 2008 Apr; 294(4):R1213-9. PubMed ID: 18287215
[TBL] [Abstract][Full Text] [Related]
15. Endothelin receptor antagonism ameliorates mast cell infiltration, vascular hypertrophy, and epidermal growth factor expression in experimental diabetes.
Gilbert RE; Rumble JR; Cao Z; Cox AJ; van Eeden P; Allen TJ; Kelly DJ; Cooper ME
Circ Res; 2000 Feb; 86(2):158-65. PubMed ID: 10666411
[TBL] [Abstract][Full Text] [Related]
16. Comparison of selective versus dual endothelin receptor antagonism on cerebrovascular dysfunction in diabetes.
Li W; Sachidanandam K; Ergul A
Neurol Res; 2011 Mar; 33(2):185-91. PubMed ID: 21801593
[TBL] [Abstract][Full Text] [Related]
17. Endothelin ET
Vercauteren M; Trensz F; Pasquali A; Cattaneo C; Strasser DS; Hess P; Iglarz M; Clozel M
J Pharmacol Exp Ther; 2017 May; 361(2):322-333. PubMed ID: 28223322
[TBL] [Abstract][Full Text] [Related]
18. Microvascular versus macrovascular dysfunction in type 2 diabetes: differences in contractile responses to endothelin-1.
Sachidanandam K; Harris A; Hutchinson J; Ergul A
Exp Biol Med (Maywood); 2006 Jun; 231(6):1016-21. PubMed ID: 16741041
[TBL] [Abstract][Full Text] [Related]
19. Antihypertensive effect of an endothelin receptor antagonist in DOCA-salt spontaneously hypertensive rats.
Schiffrin EL; Sventek P; Li JS; Turgeon A; Reudelhuber T
Br J Pharmacol; 1995 Aug; 115(8):1377-81. PubMed ID: 8564194
[TBL] [Abstract][Full Text] [Related]
20. Long-term endothelin receptor blockade improves cardiovascular function in diabetes.
Verma S; Arikawa E; McNeill JH
Am J Hypertens; 2001 Jul; 14(7 Pt 1):679-87. PubMed ID: 11465653
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
